Illicit drugs and cardiac arrhythmias in athletes

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 14, Issue 4, 2007, Pages 487-494

  Furlanello, Francesco ^a,b   Serdoz, Laura Vitali ^a   Cappato, Riccardo ^a   De Ambroggi, Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Arrhythmias; Athletes; Doping; Illicit drugs

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; ANABOLIC AGENT; ANDROGEN; ANTIESTROGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CANNABINOID; CLENBUTEROL; COCAINE; CORTICOTROPIN; DIURETIC AGENT; EPHEDRINE; ERYTHROPOIETIN; FORMOTEROL; FUROSEMIDE; GLUCOCORTICOID; GONADOTROPIN; HORMONE; HUMAN GROWTH HORMONE; ILLICIT DRUG; INSULIN; NARCOTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYGEN; SALBUTAMOL; SALMETEROL; SOMATOMEDIN C; TERBUTALINE;

ACROMEGALY; ARRHYTHMOGENESIS; ARTHRALGIA; ASTHENIA; ATHLETIC REHABILITATION; AUTONOMIC DYSFUNCTION; BLOOD VISCOSITY; CARTILAGE CALCIFICATION; CHONDROPATHY; COLLAGEN DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DEHYDRATION; DIABETES MELLITUS; DOPING; DRUG ABUSE; EXTRASYSTOLE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART HYPERTROPHY; HEART INFARCTION; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOKALEMIA; IMMUNE DEFICIENCY; INSULIN RESISTANCE; INTERNATIONAL COOPERATION; LAW ENFORCEMENT; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; LIVER TUMOR; LUNG EMBOLISM; MENTAL DISEASE; MYALGIA; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; QT PROLONGATION; REENTRY ARRHYTHMIA; REVIEW; SIDE EFFECT; SPORTS MEDICINE; STROKE; SUDDEN DEATH; TENDON DISEASE; TESTIS ATROPHY; TESTIS HYPOTROPHY; THROMBOEMBOLISM; THYROID DISEASE; VIRILIZATION; WOLFF PARKINSON WHITE SYNDROME;

ARRHYTHMIAS, CARDIAC; DOPING IN SPORTS; HUMANS; SPORTS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 34547822380     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3280ecfe3e     Document Type: Review

References (99)

1. Thiene G, Basso C, Corrado D. Pathology of sudden death in young athletes: European experience. In: Bayes de Luna A, Furlanello F, Maron BJ, Zipes DP, editors. Arrhytmias and sudden death in athletes. Dordrecht: Kluwer Academic Publishers; 2000. Chap. 5: pp. 49-69.
2. Furlanello F, Bertoldi A, Fernando F, Biffi A. Competitive athletes with arrhythmias. Classification, evaluation and treatment. In: Bayes de Luna A, Furlanello F, Maron BJ, Zipes DP, editors. Arrhythmias and sudden death in athletes. Dordrecht: Kluwer Academic Publishers; 2000. pp. 89-105.
3. Maron BJ. The paradox of exercise. N Engl J Med 2000; 343: 1409-1411.
4. Pipe A. The adverse effects of elite competition on health and well-being. Can J Appl Physiol 2001; 26 (Suppl):S192-S201.
5. Furlanello F, Fernando F, Galassi A, Bertoldi A. Ventricular arrhythmias in apparently healthy athletes. In: Malik M, editor. Risk of arrhythmia and sudden death. London: BMJ Books; 2001. pp. 316-324.
6. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349:1064-1075.
7. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003; 42:1959-1963.
8. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res 2001; 50:399-408.
9. Furlanello F, Bentivegna S, Cappato R, De Ambroggi L. Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J 2003; 4:829-837.
10. Gauthier J. The heart and doping. Arch Mal Coeur Vaiss 2006; 99:1126-1129.
11. Estes M III, Link MS, Cannom D, Naccarelli GV, Prystowsky EN, Maron BJ, et al. Report of the NASPE policy conference on arrhythmias and the athlete. J Cardiovasc Electrophysiol 2001; 12:1208-1219.
12. 36th Bethesda Conference. Eligibility recommendation for competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2005; 45:1313-1375.
13. Deligiannis A, Bjornstand H, Carre F, Heidbuchel H, Kouidi E, Panhuyzen-Goedkoop NM, et al. on behalf of the ESC Study Group of Sports Cariology. ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil 2006; 13:687-694.
14. Yesalis CE, Bahrke MS. Doping among adolescent athletes. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14:25-35.
15. Nilsson S, Baigi A, Marklund B, Fridlund B. The prevalence of use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health 2001; 11:195-197.
16. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med 2002; 32:285-296.
17. Karila T, Hovatta O, Seppala T. Concomitant abuse of anabolic androgenic steroids and human chorionico gonadotrophin impairs spermatogenesis in power athletes. Int J Sports Med 2004; 25:257-263.
18. Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 2003; 24:337-343.
19. Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. CNS Drugs 2005; 19:571-595.
20. Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med 2001; 11:254-259.
21. Congeni J, Miller S. Supplements and drugs used to enhance athletic performance. Pediatr Clin North Am 2002; 49:435-461.
22. Pipe A, Ayotte C. Nutritional supplements and doping. Clin J Sport Med 2002; 12:245-249.
23. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995; 27:1252-1262.
24. Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk 1997; 4:363-366.
25. Lenders JW, Demacker PN, Vos JA. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body-builders. J Sports Med 1988; 9:19-23.
26. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998; 41:1-15.
27. Laseter JT, Russel JA. Anabolic steroids induced tendon pathology: a review of the literature. Med Sci Sports Exerc 1991; 23:1-3.
28. Dhar R, Stout W, Link SM, Homoud MK, Weinstock J, Estes M III. Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc 2005; 80:1307-1315.
29. McCarthy K, Tang A, Dalrymple-Hay M. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg 2000; 70:658-660.
30. Kloner AR. Illicit drug use in the athlete as a contributor to cardiac events. In: Estes NA, Salem DN, Wang PJ, editors. Sudden cardiac death in the athlete. Armonk, NY: Futura Publishing Co.; 1998. pp. 441-451.
31. Schollert PV, Bendixen PM. Dilated cardiomyopathy in a user of anabolic steroids. Ugeskr Laeger 1993; 155:1217-1218.
32. Ferrera PC, Putnam DL, Verdile VP. Anabolic steroid use as the possible precipitation of dilated cardiomyopathy. Cardiology 1997; 88:218-220.
33. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart 2004; 90:473-475.
34. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 2004; 90:496-501.
35. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000; 21:225-227.
36. Thiblin L, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci 2000; 45:16-23.
37. Fineschi V, Baroldi G, Monciotti F, Pagliacci Reattelli L, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 2001; 125:253-255.
38. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34:513-554.
39. Sullivan ML, Martinez CM, Gallagher EJ. Atrial Fibrillation and anabolic steroids. J Emerg Med 1999; 17:851-857.
40. Nieminen MS, Ramo MP, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996; 17:1576-1583.
41. Stolt A, Karila T, Viitasalo M, Mantysaari M, Kujala UM, Karjalainen J. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol 1999; 84:364-366, A9.
42. Jlekmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 2000; 1:11-31.
43. Wilber RL. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med 2002; 32:125-142.
44. Hainline B. Blood doping, erytropoietin and drug testing in athletes. In: Waller BF, Harvey WP, editors. Cardiovascular evaluation of athletes: toward recognizing athletes at risk for sudden death. Newton NJ: Laennec Publishing; 1993. pp. 129-137.
45. Tokish JM, Kocher MS, Hawkins RJ. Ergogenic aids: a review of basic science, performance, side effects, and status in sports. Am J Sports Med 2004; 32:1543-1553.
46. Scheen AJ. Pharma-clinics: doping with erythropietin or the misuse of therapeutic advances. Rev Med Liege 1998; 43:499-502.
47. Noakes TD. Tainted glory. Doping and athletic performance. N Engl J Med 2004; 351:847-849.
48. Pirnary F. Doping in sports. Rev Med Liege 2001; 56:265-268.
49. De Paolo EF, Gatti R, Lancerin F, Cappellin E, Spinella P. Correlations of growth hormone (GH) and insulin-like growth factor I (IGF-I): effects of exercise and abuse by athletes. Clin Chim Acta 2001; 305:1-17.
50. Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P. Human growth hormone doping in sport. Br J Sports Med 2006; 40 (Suppl 1): i35-i39.
51. Ehrnborg C, Bengtsson BA, Rosen T. Growth hormone abuse. Pract Res Clin Endocrinol Metab 2000; 14:71-77.
52. Dean H. Does exogenous hormone improve athletic performance? Clin J Sport Med 2002; 12: 250-253.
53. Rosen T. Supraphysiological doses of growth hormone: effects on muscles and collagen in healthy active young adults. Horm Res 2006; 66 (Suppl 1): 98-104.
54. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792.
55. Clayton RN. Cardiovascular function in acromegaly. Endocrine reviews 2003; 24:272-277.
56. Hipp AA, Heitkamp HC, Rocker K, Dickhuth HH. Hypertrophic cardiomyopathy - sports - related aspects of diagnosis, therapy and sports eligibility. Int J Sports Med 2004; 25:20-26.
57. Shulman DI, Root AW, Diamond FB, Bercu BB, Martinez R, Boucek RJ Jr. Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency. J Clin Endocrinol Metab 2003; 88:4095-4099.
58. Meyers DE, Cuneo RC. Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc 2003; 78:1521-1526.
59. Goldspink G. Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting. Int J Biochem Cell Biol 2006; 38:481-489.
60. Steinacker JM, Lormes W, Reissnecker S, Liu Y. New aspects of the hormone and cytokine response to training. Eur J Appl Physiol 2004; 91:382-391.
61. Carlsen KH, Hem E, Stensrud T, Held T, Herland K, Mowinckel P. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes. Respir Med 2001; 95:571-576.
62. Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, Vardas PE. Acute electrophysiologic effects of inhaled salbutamol in human. Chest 2005; 127:2057-2063.
63. Bouchard R, Weber AR, Geiger JD. Informed decision-making on sympathomimetic use in sport and health. Clin J Sport Med 2002; 12:209-224.
64. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic peformance: a meta-analysis. JAMA 2003; 289:1537-1545.
65. McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, White CM. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA 2004; 291:216-221.
66. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements contraining ephedra alkaloids. N Engl J Med 2000; 343:1833-1838.
67. Zahn KA, Li RL, Purssell RA. Cardiovascular toxicity after ingestion of 'herbal ecstacy'. J Emerg Med 1999; 17:289-291.
68. Carson P, Oldroyd K, Phadke K. Myocardial infarction due to amphetamine. Br Med J Clin Res Ed 1987; 294:1525-1526.
69. Clark BM, Schonfield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy 2005; 25:756-761.
70. Naik SD, Freudenberger RS. Ephedra-associated cardiomyopathy. Ann Pharmacother 2004; 38:400-403.
71. Nissen SE. ADHD Drugs and cardiovascular risk. N Engl J Med 2006; 354:1445-1448.
72. Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol 1995; 25:113-132.
73. Karch SB. Cocaine cardiovascular toxicity. Southern Med J 2005; 98:794-799.
74. Hale SL, Lehmann MH, Kloner RA. Electrocardiographic abnormalities after acute administration of cocaine in the rat. Am J Cardiol 1989; 63:1529-1530.
75. Taylor D, Paroish D, Thompson K, Cavaliere M. Cocaine induced prolongation of the QT interval. Emerg Med J 2004; 21:252-253.
76. Magnano AR, Talathoti NB, Hallur R, Jurus DT, Dizon J, Holleran S, et al. Effect of Acute Cocaine Administration on the QTc Interval of Habitual Users. Am J Cardiol 2006; 97:1244-1246.
77. Guo J, Gang H, Zhang S. Molecular determinants of cocaine block of hERG potassium channels. J Pharmacol Exp Ther 2006; 317:865-874.
78. Bauman JL, Grawe JJ, Winecoff AP, Hariman RJ. Cocaine-related sudden cardiac death: a hypothesis correlating basic science and clinical observations. J Clin Pharmacol 1994; 34:902-911.
79. Parker RB, Perry GY, Horan LG, Flowers NC. Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram. J Cardiovasc Pharmacol 1999; 34:864-869.
80. Littmann L, Monroe Mh, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000; 75:845-849.
81. Perera R, Kraebber A, Schwartz MJ. Prolonged QT interval and cocaine use. J Electrocardiol 1997; 30:337-339.
82. Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992; 10:169-177.
83. Turhan H, Aksoy Y, Ozgun Tekin G, Yetkin E. Cocaine-induced acute myocardial infarction in young individuals with otherwise normal coronary risk profile: Is coronary microvascular dysfunction one of the underlying mechanisms? Int J Cardiol 2007; 114:106-107.
84. Fineschi V, Silver MD, Karch SB, Parolini M, Turillazzi E, Pomara C, Baroldi G. Myocardial disarray: an architectural disorganization linked with adrenergic stress? Int J Cardiol 2005; 99:277-282.
85. Brickner ME, Willard JE, Eichhorn EJ, Black J, Grayburn PA. Left ventricular hypertrophy associated with chronic cocaine abuse. Circulation 1991; 84:1130-1135.
86. Su J, Li J, Li W, Altura B, Altura B. Cocaine induces apoptosis in primary cultured rat aortic vascular smooth muscle cells: possible relationship to aortic dissection, atherosclerosis, and hypertension. Int J Toxicol 2004; 23:233-237.
87. He J, Xiao Y, Zhang L. Cocaine induces apoptosis in human coronary artery endothelial cells. J Cardiovasc Pharmacol 2000; 35:572-580.
88. Friedman RA. The Changing face of teenage drug abuse. The trend toward prescription drugs. N Engl J Med 2006; 354:1448-1450.
89. Fanoe S, Jensen GB, Ege P. Proarrhythmic effect of methadone: an alternative explanation of sudden death in heroine addicts. PACE 2006; 29 (Suppl 1):S30.
90. Campos DR, Yonamine M, de Moraes Moreau RL. Marijuana as doping in sports. Sports Med 2003; 33:395-399.
91. Lorente FO, Peretti-Watel P, Grelot L. Cannabis use to enhance sportive and non-sportive performances among French sport students. Addict Behav 2005; 30:1382-1391.
92. Lindsay AC, Foale RA, Warren O, Henry JA. Cannabis as a precipitant of cardiovascular emergencies. Int J Cardiol 2005; 104:230-232.
93. Fisher BA, Ghuran A, Vadamalai V, Antonios TF. Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J 2005; 22:679-680.
94. Whyte G, Stephens N, Sharma S, Shave R, Budgett R, McKenna WJ. Spontaneus atrial fibrillation in a freestyle skier. Br J Sports Med 2004; 38:230-232.
95. Pirwitz MJ, Willard JE, Landau C, Lange RA, Glamann DB, Kessler DJ, et al. Influence of cocaine, ethanol, or their combination on epicardial coronary arterial dimensions in humans. Arch Intern Med 1995; 155:1186-1191.
96. Randall T. Cocaine, alcohol mix in body to form even longer lasting, more lethal drug. JAMA 1992; 267:1043-1044.
97. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69-74.
98. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002; 91:21-26.
99. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10:189-194.